{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:24:43Z","timestamp":1787660683743,"version":"build-2736575974"},"reference-count":241,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med. Technol."],"abstract":"<jats:p>The incidence of diabetes mellitus (DM) is increasing worldwide, especially for its major renal complications, diabetic nephropathy (DN) and chronic kidney disease (CKD). These are caused by chronic hyperglycemia, oxidative stress, hemodynamics, inflammation, and profibrotic signaling, which result in progressive renal structural damage and functional decline. All these mechanisms contribute to podocyte injury, thickening of the glomerular basement membrane, interstitial fibrosis, and progressive loss of renal function. While traditional diagnostic markers like albuminuria or estimated glomerular filtration rate (eGFR) aid in tracking disease with imaging, and emerging markers like neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and cystatin C can help, none can detect early, subclinical kidney damage. A comprehensive literature review was conducted in PubMed, Google Scholar, Scopus, Web of Science, and ScienceDirect using keywords related to DN pathophysiology, diagnosis, nanomedicine, renal targeting, and nanoformulations, with publications between 2015 and 2026. Intensive glycemic and blood pressure control, inhibition of the renin-angiotensin-aldosterone system, and lipid-lowering therapy are currently used as therapeutic interventions. Poor bioavailability, off-target toxicity, complex dosing regimens, and variable renal drug handling are often responsible for their limited effectiveness. One approach to circumventing these limitations is with nanotechnology-based drug delivery systems. In preclinical studies, the antioxidant, anti-inflammatory, and antifibrotic effects have consistently been reported to be superior, with reduced systemic toxicity, while clinical translation remains in its early stages. This review discusses current knowledge on DN and critically evaluates the pros, cons, and future of nanotechnology-based approaches for delivering targeted nanomedicines to the kidney.<\/jats:p>","DOI":"10.3389\/fmedt.2026.1951734","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:47:57Z","timestamp":1787658477000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Translational advances in diabetic nephropathy management: integrating nanoformulation-based drug delivery systems"],"prefix":"10.3389","volume":"8","author":[{"given":"Mohd Danish","family":"Ansari","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Vishwakarma","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy & Phytochemistry, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md","family":"Quamuddin","sequence":"additional","affiliation":[{"name":"Metro College of Health Sciences and Research","place":["Greater Noida, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Raj Kumar Goel Institute of Technology (Pharmacy)","place":["Ghaziabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashim","family":"Khan","sequence":"additional","affiliation":[{"name":"Metro College of Health Sciences and Research","place":["Greater Noida, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Fauzi","family":"Abd Jalil","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil Farooq","family":"Wali","sequence":"additional","affiliation":[{"name":"RAK College of Pharmacy, RAK Medical and Health Sciences University","place":["Ras Al Khaimah, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirajunisa","family":"Talath","sequence":"additional","affiliation":[{"name":"RAK College of Pharmacy, RAK Medical and Health Sciences University","place":["Ras Al Khaimah, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Tanani","sequence":"additional","affiliation":[{"name":"RAK College of Pharmacy, RAK Medical and Health Sciences University","place":["Ras Al Khaimah, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","author":"Genitsaridi","year":""},{"key":"B2","first-page":"34","article-title":"Understanding diabetes Mellitus: a descriptive study of its types, causes and health impacts","volume":"3","author":"Maity","year":"2025","journal-title":"Bharati Int J Multidiscip"},{"key":"B3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.37022\/wjcmpr.v5i5.294","article-title":"Profiling of clinical dynamics of type 2 diabetes mellitus in patients: a perspective review","volume":"5","author":"Ikwuka","year":"2023","journal-title":"World J Curr Med Pharm Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e030524229631","DOI":"10.2174\/0115733998291870240408043837","article-title":"Therapeutic interventions for diabetes Mellitus-associated complications","volume":"21","author":"Pradhan","year":"2025","journal-title":"Curr Diabetes Rev"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-031-32047-7_68-1","article-title":"The global burden of disease: a focus on type II diabetes","volume-title":"Handbook of Public Health Nutrition: International, National, and Regional Perspectives","author":"Forray","year":"2025"},{"key":"B6","first-page":"119","article-title":"Risk factors for diabetic nephropathy in diabetic patients","volume":"14","author":"Oleiwi","year":"2022","journal-title":"Iran J War Public Health"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1497449","DOI":"10.1155\/2021\/1497449","article-title":"Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment","volume":"2021","author":"Samsu","year":"2021","journal-title":"BioMed Res Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/a-2435-8264","article-title":"Diabetic nephropathy: pathogenesis, mechanisms, and therapeutic strategies","volume":"57","author":"Dwivedi","year":"2024","journal-title":"Horm Metab Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/kidneydial2030038","article-title":"The epidemiology of diabetic kidney disease","volume":"2","author":"Hoogeveen","year":"2022","journal-title":"Kidney Dialysis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/life13020539","article-title":"The mechanism of hyperglycemia-induced renal cell injury in diabetic nephropathy disease: an update","volume":"13","author":"Wu","year":"2023","journal-title":"Life"},{"key":"B11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/j.1365-2362.2004.01429.x","article-title":"New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology","volume":"34","author":"Wolf","year":"2004","journal-title":"Eur J Clin Investig"},{"key":"B12","doi-asserted-by":"publisher","first-page":"01","DOI":"10.61920\/jimp.v1i02.22","article-title":"Revisiting and expanding the understanding of molecular mechanisms underpinning diabetic nephropathy: an updated and comprehensive review of recent advance","volume":"1","author":"Manwar","year":"2024","journal-title":"J Intern Med Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3390\/life12081202","article-title":"Up-date on diabetic nephropathy","volume":"12","author":"Pelle","year":"2022","journal-title":"Life"},{"key":"B14","first-page":"1162","article-title":"Molecular mechanisms of diabetic nephropathy, general preventive measures and novel therapeutic strategies","volume":"7","author":"Sherzay","year":"2018","journal-title":"Int J Sci Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.18520\/cs\/v124\/i8\/899-909","article-title":"Diabetic nephropathy: prevalence, pathogenesis and signalling pathways","volume":"124","author":"Chintala","year":"2023","journal-title":"Curr Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/biomedicines12051098","article-title":"Diabetes and renal complications: an overview on pathophysiology, biomarkers and therapeutic interventions","volume":"12","author":"Jha","year":"2024","journal-title":"Biomedicines"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.ekir.2018.05.008","article-title":"Application of a nanotechnology-based, point-of-care diagnostic device in diabetic kidney disease","volume":"3","author":"Kumar","year":"2018","journal-title":"Kidney Int Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"103159","DOI":"10.1016\/j.dsx.2024.103159","article-title":"Nanotechnology as a potential treatment for diabetes and its complications: a review","volume":"18","author":"Manral","year":"2024","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"870049","DOI":"10.3389\/fbioe.2022.870049","article-title":"Nano-technological approaches for targeting kidney diseases with focus on diabetic nephropathy: recent progress, and future perspectives","volume":"10","author":"Lin","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s10020-024-00824-9","article-title":"An update on chronic complications of diabetes mellitus: from molecular mechanisms to therapeutic strategies with a focus on metabolic memory","volume":"30","author":"Yang","year":"2024","journal-title":"Mol Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1185317","DOI":"10.3389\/fimmu.2023.1185317","article-title":"Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols","volume":"14","author":"Jin","year":"2023","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.2174\/092986710793348581","article-title":"Oxidative stress in diabetic nephropathy","volume":"17","author":"Kashihara","year":"2010","journal-title":"Curr Med Chem"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.2174\/138161207781662957","article-title":"The podocyte: a potential therapeutic target in diabetic nephropathy?","volume":"13","author":"Marshall","year":"2007","journal-title":"Curr Pharm Des"},{"key":"B24","first-page":"45","article-title":"Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links","volume":"11","author":"Oguntibeju","year":"2019","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"121661","DOI":"10.1016\/j.lfs.2023.121661","article-title":"Oxidative stress as a culprit in diabetic kidney disease","volume":"322","author":"Su","year":"2023","journal-title":"Life Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11892-016-0735-5","article-title":"Podocytes: the weakest link in diabetic kidney disease?","volume":"16","author":"Lin","year":"2016","journal-title":"Curr Diab Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/MNH.0b013e3282f2904d","article-title":"The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy?","volume":"17","author":"Reddy","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B28","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2337\/diacare.28.3.745","article-title":"Diabetic nephropathy","volume":"28","author":"Bloomgarden","year":"2005","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/1573399052952622","article-title":"Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology","volume":"1","author":"Gruden","year":"2005","journal-title":"Curr Diabetes Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"09603271221143713","DOI":"10.1177\/09603271221143713","article-title":"Bisacurone attenuates diabetic nephropathy by ameliorating oxidative stress, inflammation and apoptosis in rats","volume":"41","author":"Yang","year":"2022","journal-title":"Hum Exp Toxicol"},{"key":"B31","first-page":"590","article-title":"Research advances in podocyte injury and its role in diabetic nephropathy","volume":"32","author":"Li","year":"2010","journal-title":"J Chin Acade Med Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"F831","DOI":"10.1152\/ajprenal.00313.2016","article-title":"Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic?","volume":"311","author":"Marshall","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3390\/ijms25053052","article-title":"TGF-\u03b2 signaling pathways in the development of diabetic retinopathy","volume":"25","author":"Callan","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"696542","DOI":"10.3389\/fcell.2021.696542","article-title":"Signaling pathways involved in diabetic renal fibrosis","volume":"9","author":"Zhang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13098-025-01726-4","article-title":"Decoding diabetic kidney disease: a comprehensive review of interconnected pathways, molecular mediators, and therapeutic insights","volume":"17","author":"Efiong","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e29871","DOI":"10.1016\/j.heliyon.2024.e29871","article-title":"NF-\u0138B axis in diabetic neuropathy, cardiomyopathy and nephropathy: a roadmap from molecular intervention to therapeutic strategies","volume":"10","author":"Rezaee","year":"2024","journal-title":"Heliyon"},{"key":"B37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1590\/1806-9282.64.01.85","article-title":"Advances in early biomarkers of diabetic nephropathy","volume":"64","author":"Zhang","year":"2018","journal-title":"Rev Assoc Med Bras"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2483990","DOI":"10.1080\/0886022X.2025.2483990","article-title":"TGF-\u03b2: elusive target in diabetic kidney disease","volume":"47","author":"Rani","year":"2025","journal-title":"Renal Fail"},{"key":"B39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cytogfr.2025.05.007","article-title":"Exploring inflammatory and fibrotic mechanisms driving diabetic nephropathy progression","volume":"84","author":"Ansari","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"key":"B40","first-page":"1059","article-title":"Signaling pathways in diabetic nephropathy","volume":"30","author":"Kawanami","year":"2016","journal-title":"Histol Histopathol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4239\/wjd.v5.i6.763","article-title":"Biomarkers in diabetic nephropathy: present and future","volume":"5","author":"Currie","year":"2014","journal-title":"World J Diabetes"},{"key":"B42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/IJNRD.S143186","article-title":"The role of novel biomarkers in predicting diabetic nephropathy: a review","volume":"10","author":"Uwaezuoke","year":"2017","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3389\/fendo.2019.00528","article-title":"Editorial: podocyte pathology and nephropathy-an update","volume":"10","author":"Lehtonen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"112292","DOI":"10.1016\/j.diabres.2025.112292","article-title":"Biomarkers in diabetic nephropathy: a comprehensive review of their role in early detection and disease progression monitoring","volume":"226","author":"Wani","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"B45","doi-asserted-by":"publisher","first-page":"98880","DOI":"10.5527\/wjn.v13.i4.98880","article-title":"Neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, and periostin: novel urinary biomarkers in diabetic nephropathy","volume":"13","author":"Varatharajan","year":"2024","journal-title":"World J Nephrol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/diagnostics15080973","article-title":"Emerging biomarkers and innovative therapeutic strategies in diabetic kidney disease: a pathway to precision medicine","volume":"15","author":"Shetty","year":"2025","journal-title":"Diagnostics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1080\/14737159.2020.1768849","article-title":"Cystatin C as a biomarker of chronic kidney disease: latest developments","volume":"20","author":"Benoit","year":"2020","journal-title":"Expert Rev Mol Diagn"},{"key":"B48","doi-asserted-by":"publisher","first-page":"382","DOI":"10.22088\/cjim.15.3.382","article-title":"Novel biomarkers for the diagnosis of diabetic nephropathy","volume":"15","author":"Concepci\u00f3n","year":"2024","journal-title":"Caspian J Intern Med"},{"key":"B49","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/1744-9987.12462","article-title":"Diagnostic accuracy of Serum cystatin C for the evaluation of renal dysfunction in diabetic patients: a meta-analysis","volume":"20","author":"Yang","year":"2016","journal-title":"Ther Apher Dial"},{"key":"B50","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3343\/alm.2018.38.6.524","article-title":"Plasma neutrophil gelatinase-associated lipocalin as a marker of tubular damage in diabetic nephropathy","volume":"38","author":"Kim","year":"2018","journal-title":"Ann Lab Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/jdi.13139","article-title":"Circulating kidney injury molecule-1 as a biomarker of renal parameters in diabetic kidney disease","volume":"11","author":"Gohda","year":"2020","journal-title":"J Diabetes Investig"},{"key":"B52","doi-asserted-by":"publisher","first-page":"8517929","DOI":"10.1155\/2018\/8517929","article-title":"Assessment of vitamin D-binding protein and early prediction of nephropathy in type 2 Saudi diabetic patients","volume":"2018","author":"Fawzy","year":"2018","journal-title":"J Diabetes Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"635","DOI":"10.4103\/jfmpc.jfmpc_1207_23","article-title":"Urinary megalin levels in patients with type 2 diabetic nephropathy and its correlation with renal function","volume":"13","author":"Jagennath","year":"2024","journal-title":"J Family Med Prim Care"},{"key":"B54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.9734\/jammr\/2024\/v36i65459","article-title":"Urinary transferrin as a marker of renal injury in diabetic individuals. An integrative review","volume":"36","author":"Gusm\u00e3o","year":"2024","journal-title":"J Adv Med Med Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e13070","DOI":"10.7759\/cureus.13070","article-title":"Evaluation of Serum ceruloplasmin levels as a biomarker for oxidative stress in patients with diabetic retinopathy","volume":"13","author":"Satyanarayana","year":"2021","journal-title":"Cureus"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41581-019-0229-1","article-title":"Type IV collagen and diabetic kidney disease","volume":"16","author":"Miner","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ki.2015.278","article-title":"Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes","volume":"89","author":"Pavkov","year":"2016","journal-title":"Kidney Int"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e3497","DOI":"10.1002\/dmrr.3497","article-title":"Monocyte chemoattractant protein-1 predicts the development of diabetic nephropathy","volume":"38","author":"Scurt","year":"2022","journal-title":"Diabetes Metab Res Rev"},{"key":"B59","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1053\/meta.2003.50096","article-title":"Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy","volume":"52","author":"Moriwaki","year":"2003","journal-title":"Metabolism"},{"key":"B60","doi-asserted-by":"publisher","first-page":"122955","DOI":"10.1016\/j.lfs.2024.122955","article-title":"Implementing losartan potassium-laden pegylated nanocubic vesicles as a novel nanoplatform to alleviate cisplatin-induced nephrotoxicity via blocking apoptosis and activating the wnt\/\u03b2-catenin\/TCF-4 pathway","volume":"354","author":"Salem","year":"2024","journal-title":"Life Sci"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2158102","DOI":"10.1080\/0886022X.2022.2158102","article-title":"The association of plasma NT-proBNP level and progression of diabetic kidney disease","volume":"45","author":"Zhao","year":"2023","journal-title":"Renal Fail"},{"key":"B62","doi-asserted-by":"publisher","first-page":"17599","DOI":"10.1038\/s41598-023-44177-5","article-title":"Periostin deficiency attenuates kidney fibrosis in diabetic nephropathy by improving pancreatic \u03b2-cell dysfunction and reducing kidney EMT","volume":"13","author":"Cho","year":"2023","journal-title":"Sci Rep"},{"key":"B63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.9734\/ijbcrr\/2020\/v29i1030238","article-title":"Review, plasma cyclophilin A as a novel biomarker in chronic nephropathy","volume":"29","author":"EL-Fattah","year":"2020","journal-title":"Int J Biochem Res Rev"},{"key":"B64","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000484284","article-title":"Uric acid and diabetic nephropathy risk","volume":"192","author":"Mauer","year":"2018","journal-title":"Contrib Nephrol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12933-018-0697-9","article-title":"Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria","volume":"17","author":"Currie","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/nyas.12758","article-title":"MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets","volume":"1353","author":"Kato","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"B67","doi-asserted-by":"publisher","first-page":"781417","DOI":"10.3389\/fendo.2021.781417","article-title":"Lipidomics reveals Serum specific lipid alterations in diabetic nephropathy","volume":"12","author":"Xu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4103\/ijn.IJN_80_19","article-title":"MicroRNA-21 as an early marker of nephropathy in patients with type 1 diabetes","volume":"30","author":"Fouad","year":"2020","journal-title":"Indian J Nephrol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1039\/D5MO00019J","article-title":"Understanding metabolic alterations in advanced stage chronic kidney disease patients by NMR-based metabolomics","volume":"21","author":"Sahu","year":"2025","journal-title":"Mol. Omics"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s13300-025-01731-w","article-title":"Urinary L-FABP: a novel biomarker for evaluating diabetic nephropathy onset and progression. A narrative review","volume":"16","author":"Satta","year":"2025","journal-title":"Diabetes Ther"},{"key":"B71","doi-asserted-by":"publisher","first-page":"4647685","DOI":"10.1155\/2016\/4647685","article-title":"Urinary markers of tubular injury in early diabetic nephropathy","volume":"2016","author":"Fiseha","year":"2016","journal-title":"Int J Nephrol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/1479164112460253","article-title":"Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients","volume":"10","author":"Kerkeni","year":"2013","journal-title":"Diabetes Vasc Dis Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3803\/EnM.2016.31.2.245","article-title":"Current challenges in diabetic nephropathy: early diagnosis and ways to improve outcomes","volume":"31","author":"Kim","year":"2016","journal-title":"Endocrinol Metab"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA consensus conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"B75","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.2337\/dc16-S012","article-title":"9. Microvascular complications and foot care","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"B76","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0272-6386(03)00826-6","article-title":"Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK) 1","volume":"42","author":"Eknoyan","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B77","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/kisup.2012.65","article-title":"Chapter 2: Definition, identification, and prediction of CKD progression","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"B78","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI Clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B79","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2337\/dc13-0985","article-title":"Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria","volume":"37","author":"Krolewski","year":"2014","journal-title":"Diabetes Care"},{"key":"B80","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/01.CIR.0000133312.96477.48","article-title":"Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes","volume":"110","author":"Klausen","year":"2004","journal-title":"Circulation"},{"key":"B81","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3346\/jkms.2010.25.11.1616","article-title":"Ethnic coefficients for glomerular filtration rate estimation by the modification of diet in renal disease study equations in the Korean population","volume":"25","author":"Lee","year":"2010","journal-title":"J Korean Med Sci"},{"key":"B83","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2337\/dc06-1688","article-title":"How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes?","volume":"30","author":"Chudleigh","year":"2007","journal-title":"Diabetes Care"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/j.1523-1755.2004.00517.x","article-title":"Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement","volume":"65","author":"Knight","year":"2004","journal-title":"Kidney Int"},{"key":"B86","doi-asserted-by":"publisher","first-page":"14791641211058856","DOI":"10.1177\/14791641211058856","article-title":"Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: a review of the literature","volume":"18","author":"Thipsawat","year":"2021","journal-title":"Diabetes Vasc Dis Res"},{"key":"B87","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbapap.2011.10.002","article-title":"Proteomics, cysteine cathepsins: from structure, function and regulation to new frontiers","volume":"1824","author":"Turk","year":"2012","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1172\/JCI7709","article-title":"Cystatin C deficiency in human atherosclerosis and aortic aneurysms","volume":"104","author":"Shi","year":"1999","journal-title":"J Clin Invest"},{"key":"B89","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/icb.2014.121","article-title":"Cystatin C is a disease-associated protein subject to multiple regulation","volume":"93","author":"Xu","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/ajkd.2002.34487","article-title":"Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis","volume":"40","author":"Dharnidharka","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"B91","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/CCM.0b013e318195846e","article-title":"Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery\u2014a prospective cohort study","volume":"37","author":"Haase-Fielitz","year":"2009","journal-title":"Crit Care Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1523-1755.2004.00861.x","article-title":"Early detection of acute renal failure by serum cystatin C","volume":"66","author":"Herget-Rosenthal","year":"2004","journal-title":"Kidney Int"},{"key":"B93","doi-asserted-by":"publisher","first-page":"c176","DOI":"10.1159\/000117814","article-title":"Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography","volume":"108","author":"Ling","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"B94","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000505155","article-title":"Neutrophil gelatinase-associated lipocalin and retinol-binding protein-4 as biomarkers for diabetic kidney disease","volume":"45","author":"Abbasi","year":"2020","journal-title":"Kidney Blood Press Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2337\/dc10-1545","article-title":"Glomerular and tubular damage markers are elevated in patients with diabetes","volume":"34","author":"Nauta","year":"2011","journal-title":"Diabetes Care"},{"key":"B96","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.clinbiochem.2015.10.016","article-title":"Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes","volume":"49","author":"de Carvalho","year":"2016","journal-title":"Clin Biochem"},{"key":"B97","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1053\/j.ajkd.2021.05.013","article-title":"Plasma kidney injury molecule 1 in CKD: findings from the Boston kidney biopsy cohort and CRIC studies","volume":"79","author":"Schmidt","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"B98","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00592-020-01656-9","article-title":"Novel biomarkers of diabetic kidney disease: current status and potential clinical application","volume":"58","author":"Barutta","year":"2021","journal-title":"Acta Diabetol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1681\/ASN.2013070758","article-title":"Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes","volume":"25","author":"Sabbisetti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/ki.2015.314","article-title":"Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes","volume":"89","author":"Nowak","year":"2016","journal-title":"Kidney Int"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1007\/s00125-011-2163-z","article-title":"Non-invasive investigation of kidney disease in type 1 diabetes by magnetic resonance imaging","volume":"54","author":"Thelwall","year":"2011","journal-title":"Diabetologia"},{"key":"B102","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s43055-025-01490-5","article-title":"3T BOLD and DW magnetic resonance imaging quantitative parameters for prediction of early diabetic nephropathy","volume":"56","author":"Ezz Eldin","year":"2025","journal-title":"Egypt J Radiol Nucl Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3390\/jcm4091761","article-title":"Non-proteinuric diabetic nephropathy","volume":"4","author":"Robles","year":"2015","journal-title":"J Clin Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1681\/ASN.2010010010","article-title":"Pathologic classification of diabetic nephropathy","volume":"21","author":"Tervaert","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1097\/IMNA-D-23-00029","article-title":"Update on the pathogenesis, diagnosis, and treatment of diabetic tubulopathy","volume":"11","author":"Liu","year":"2024","journal-title":"Integr Med Nephrol Androl"},{"key":"B108","doi-asserted-by":"publisher","first-page":"20","DOI":"10.36922\/imo.7520","article-title":"Diabetes mellitus: an updated overview and role of medicinal plants in modern treatment","volume":"2","author":"Vishwakarma","year":"2025","journal-title":"Innov Medi Omics"},{"key":"B109","first-page":"224","article-title":"The role of nutrition in the management of health and diseases","volume":"15","author":"Sharma","year":"2024","journal-title":"Indian J Nat Prod Resour"},{"key":"B110","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/dom.13987","article-title":"Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY","volume":"22","author":"Rhee","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B111","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0272-6386(00)70018-7","article-title":"Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials","volume":"35","author":"Kshirsagar","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"S330","DOI":"10.21037\/atm.2019.09.117","article-title":"The SONAR study\u2014is there a future for endothelin receptor antagonists in diabetic kidney disease?","volume":"7","author":"Cahn","year":"2019","journal-title":"Ann Transl Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1053\/j.ajkd.2008.01.025","article-title":"The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis","volume":"52","author":"McCormick","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"B117","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12933-018-0682-3","article-title":"Rationale, design, and baseline characteristics of the CArdiovascular safety and renal microvascular outcomE study with LINAgliptin (CARMELINA\u00ae): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk","volume":"17","author":"Rosenstock","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.2337\/dc14-S120","article-title":"Nutrition therapy recommendations for the management of adults with diabetes","volume":"37","author":"Evert","year":"2014","journal-title":"Diabetes Care"},{"key":"B119","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13287-024-03647-x","article-title":"Amelioration of diabetic nephropathy in mice by a single intravenous injection of human mesenchymal stromal cells at early and later disease stages is associated with restoration of autophagy","volume":"15","author":"He","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"B120","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2337\/dc13-2113","article-title":"Kidney disease and related findings in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study","volume":"37","author":"De Boer","year":"2014","journal-title":"Diabetes Care"},{"key":"B121","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.2337\/dc20-0226","article-title":"An observational study of the equivalence of age and duration of diabetes to glycemic control relative to the risk of complications in the combined cohorts of the DCCT\/EDIC study","volume":"43","author":"Bebu","year":"2020","journal-title":"Diabetes Care"},{"key":"B122","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"de Boer","year":"2020","journal-title":"Kidney Int"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","article-title":"Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial","volume":"143","author":"Ye","year":"2021","journal-title":"Circulation"},{"key":"B124","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B125","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"B126","doi-asserted-by":"publisher","first-page":"212249","DOI":"10.7573\/dic.212249","article-title":"Therapeutic approaches to slowing the progression of diabetic nephropathy\u2013is less best?","volume":"2013","author":"Vivian","year":"2013","journal-title":"Drugs Context"},{"key":"B127","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2337\/dc11-S011","article-title":"Standards of medical care in diabetes\u20142011","volume":"34","year":"2011","journal-title":"Diabetes Care"},{"key":"B128","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1046\/j.1523-1755.2000.00880.x","article-title":"Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy","volume":"57","author":"Andersen","year":"2000","journal-title":"Kidney Int"},{"key":"B129","first-page":"189","article-title":"Comparing the efficacy of angiotensin converting enzyme inhibitors with calcium channel blockers on the treatment of diabetic nephropathy: a meta-analysis","volume":"48","author":"Zhang ZhaoWei","year":"2019","journal-title":"Iran J Public Health"},{"key":"B130","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.diabres.2005.02.019","article-title":"Renoprotective effect of diltiazem in hypertensive type 2 diabetic patients with persistent microalbuminuria despite ACE inhibitor treatment","volume":"70","author":"P\u00e9rez-Maraver","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"B131","first-page":"1","article-title":"Role of calcium channel blockers in diabetic nephropathy","volume":"1","author":"Sheikh","year":"2020","journal-title":"Multi-Knowledge Electron Comprehens J Educ Sci Public"},{"key":"B132","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/hr.2014.110","article-title":"Impact of combined losartan\/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension","volume":"37","author":"Fujisaki","year":"2014","journal-title":"Hypertens Res"},{"key":"B133","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1159\/000517020","article-title":"The forgotten antiproteinuric properties of diuretics","volume":"52","author":"Trujillo","year":"2021","journal-title":"Am J Nephrol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S2213-8587(14)70030-0","article-title":"Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial","volume":"2","author":"Kwakernaak","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1503711","DOI":"10.3389\/fendo.2025.1503711","article-title":"Lipid abnormality in diabetic kidney disease and potential treatment advancements","volume":"16","author":"Tu","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.12669\/pjms.37.5.4045","article-title":"Atorvastatin calcium tablets on inflammatory factors, hemorheology and renal function damage indexes in patients with diabetic nephropathy","volume":"37","author":"Li","year":"2021","journal-title":"Pak J Med Sci"},{"key":"B137","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12944-016-0350-0","article-title":"Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials","volume":"15","author":"Shen","year":"2016","journal-title":"Lipids Health Dis"},{"key":"B138","doi-asserted-by":"publisher","first-page":"e2901","DOI":"10.1002\/dmrr.2901","article-title":"The effect of statins on renal outcomes in patients with diabetic kidney disease: a systematic review and meta-analysis","volume":"33","author":"Qin","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"B139","doi-asserted-by":"publisher","first-page":"115481557","DOI":"10.21037\/apm-21-2673","article-title":"Effect of statins on the treatment of early diabetic nephropathy: a systematic review and meta-analysis of nine randomized controlled trials","volume":"10","author":"Lv","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B140","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ekir.2018.09.006","article-title":"Associations of fenofibrate therapy with incidence and progression of CKD in patients with type 2 diabetes","volume":"4","author":"Frazier","year":"2019","journal-title":"Kidney Int Rep"},{"key":"B141","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/jcmm.13983","article-title":"Exploring macrophage cell therapy on diabetic kidney disease","volume":"23","author":"Guiteras","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1111\/jcmm.14237","article-title":"Chemerin\/ChemR23 axis promotes inflammation of glomerular endothelial cells in diabetic nephropathy","volume":"23","author":"Shang","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B143","doi-asserted-by":"publisher","first-page":"F1358","DOI":"10.1152\/ajprenal.00332.2011","article-title":"Monocyte\/macrophage chemokine receptor CCR2 mediates diabetic renal injury","volume":"301","author":"Awad","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1199173","DOI":"10.3389\/fimmu.2023.1199173","article-title":"T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/biom12040542","article-title":"Advanced glycation end products and diabetes mellitus: mechanisms and perspectives","volume":"12","author":"Khalid","year":"2022","journal-title":"Biomolecules"},{"key":"B146","doi-asserted-by":"publisher","first-page":"4826724","DOI":"10.1155\/2017\/4826724","article-title":"The Nrf2\/Keap1\/ARE pathway and oxidative stress as a therapeutic target in type II diabetes mellitus","volume":"2017","author":"David","year":"2017","journal-title":"J Diabetes Res"},{"key":"B147","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13020-022-00700-w","article-title":"Effects of antioxidants on diabetic kidney diseases: mechanistic interpretations and clinical assessment","volume":"18","author":"Sun","year":"2023","journal-title":"Chin Med"},{"key":"B148","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc14-S014","article-title":"Standards of medical care in diabetes\u20142014","volume":"37","author":"Care","year":"2014","journal-title":"Diabetes Care"},{"key":"B149","first-page":"1","article-title":"Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"B150","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1017\/S000711452400103X","article-title":"The blood pressure control effect of the sodium-restricted dietary approaches to stop hypertension diet: a systematic review","volume":"132","author":"Kim","year":"2024","journal-title":"Br J Nutr"},{"key":"B151","doi-asserted-by":"crossref","first-page":"F919","DOI":"10.1152\/ajprenal.00068.2011","article-title":"The western-style diet: a major risk factor for impaired kidney function and chronic kidney disease","volume":"301","author":"Odermatt","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.3390\/nu16121918","article-title":"Nutritional strategies against diabetic nephropathy: insights from animal studies and human trials","volume":"16","author":"Zhou","year":"2024","journal-title":"Nutrients"},{"key":"B153","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"key":"B154","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41746-024-01114-8","article-title":"Effectiveness of DialBetesPlus, a self-management support system for diabetic kidney disease: randomized controlled trial","volume":"7","author":"Waki","year":"2024","journal-title":"NPJ Digit Med"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1385872","DOI":"10.3389\/fendo.2024.1385872","article-title":"Effects of dietary intervention on diabetic nephropathy: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials","volume":"15","author":"Cai","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B156","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/nu15010097","article-title":"Mediterranean Diet and chronic kidney disease (CKD): a practical approach","volume":"15","author":"P\u00e9rez-Torres","year":"2022","journal-title":"Nutrients"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dci23-0030","article-title":"Diabetic nephropathy: update on pillars of therapy slowing progression","volume":"46","author":"Naaman","year":"2023","journal-title":"Diabetes Care"},{"key":"B158","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.2147\/DMSO.S380550","article-title":"Current strategies and potential prospects for nanoparticle-mediated treatment of diabetic nephropathy","volume":"15","author":"Liu","year":"2022","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"B159","doi-asserted-by":"publisher","first-page":"1236686","DOI":"10.3389\/fendo.2023.1236686","article-title":"Nanomedicines for the management of diabetic nephropathy: present progress and prospects","volume":"14","author":"Paul","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B160","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/ph17050625","article-title":"Research progress of drug delivery systems targeting the kidneys","volume":"17","author":"Huang","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B161","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/molecules26020272","article-title":"Chitosan nanoparticles-insight into properties, functionalization and applications in drug delivery and theranostics","volume":"26","author":"Jhaveri","year":"2021","journal-title":"Molecules"},{"key":"B162","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/ki.2014.128","article-title":"Diabetic kidney disease: a clinical update from kidney disease: improving global outcomes","volume":"87","author":"Molitch","year":"2015","journal-title":"Kidney Int"},{"key":"B163","doi-asserted-by":"publisher","first-page":"100020","DOI":"10.1016\/j.crphar.2021.100020","article-title":"Drug-drug interactions in polypharmacy patients: the impact of renal impairment","volume":"2","author":"Papotti","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"B164","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4103\/amhs.amhs_11_18","article-title":"The burden of polypharmacy and pattern of comorbidities among chronic kidney disease patients in clinical practice","volume":"6","author":"Fasipe","year":"2018","journal-title":"Arch Med Health Sci"},{"key":"B165","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1159\/000518454","article-title":"Impact of polypharmacy on health-related quality of life in dialysis patients","volume":"52","author":"Colombijn","year":"2021","journal-title":"Am J Nephrol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"100042","DOI":"10.1016\/j.dmd.2025.100042","article-title":"A review of physiologically based pharmacokinetic modeling of renal drug disposition","volume":"53","author":"Huang","year":"2025","journal-title":"Drug Metab Dispos"},{"key":"B167","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.mcna.2004.11.007","article-title":"Drug dosing in chronic kidney disease","volume":"89","author":"Gabardi","year":"2005","journal-title":"Med Clin"},{"key":"B168","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.3390\/ijms22094824","article-title":"Kidney disease in diabetic patients: from pathophysiology to pharmacological aspects with a focus on therapeutic inertia","volume":"22","author":"Gembillo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B169","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.3390\/nu14204383","article-title":"Combined supplementation of coenzyme Q10 and other nutrients in specific medical conditions","volume":"14","author":"Tippairote","year":"2022","journal-title":"Nutrients"},{"key":"B170","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/08982104.2020.1780607","article-title":"Effect of glutathione liposomes on diabetic nephropathy based on oxidative stress and polyol pathway mechanism","volume":"31","author":"Shen","year":"2021","journal-title":"J Liposome Res"},{"key":"B171","doi-asserted-by":"publisher","first-page":"101409","DOI":"10.1016\/j.jddst.2019.101409","article-title":"Study of the target effect of mannose modified liposomes on diabetic rat kidney based on GLUT","volume":"55","author":"Yang","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12906-019-2531-7","article-title":"The effects of a hirudin\/liposome complex on a diabetic nephropathy rat model","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Complement Altern Med"},{"key":"B173","doi-asserted-by":"publisher","first-page":"e68807","DOI":"10.7759\/cureus.68807","article-title":"The science of solid lipid nanoparticles: from fundamentals to applications","volume":"16","author":"M","year":"2024","journal-title":"Cureus"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.22038\/IJBMS.2019.13989","article-title":"Antioxidant, anti-apoptotic, and protective effects of myricitrin and its solid lipid nanoparticle on streptozotocin-nicotinamide-induced diabetic nephropathy in type 2 diabetic male mice","volume":"22","author":"Ahangarpour","year":"2019","journal-title":"Iran J Basic Med Sci"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1846780","DOI":"10.3389\/fnano.2026.1846780","article-title":"Gold nanomaterials in the diagnosis and treatment of kidney diseases: from fundamental transport mechanisms to clinical translation prospects","volume":"8","author":"Liu","year":"2026","journal-title":"Front Nanotechnol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1016\/j.nxnano.2023.100013","article-title":"Current updated review on preparation of polymeric nanoparticles for drug delivery and biomedical applications","volume":"2","author":"Bhardwaj","year":"2023","journal-title":"Next Nanotechnol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.3390\/molecules25163731","article-title":"Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology","volume":"25","author":"Zieli\u0144ska","year":"2020","journal-title":"Molecules"},{"key":"B178","doi-asserted-by":"publisher","first-page":"103393","DOI":"10.1016\/j.drudis.2022.103393","article-title":"Progress in oral insulin delivery by PLGA nanoparticles for the management of diabetes","volume":"28","author":"Pang","year":"2023","journal-title":"Drug Discov Today"},{"key":"B179","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.2147\/IJN.S166445","article-title":"Kidney-targeted drug delivery via rhein-loaded polyethyleneglycol-co-polycaprolactone-co-polyethylenimine nanoparticles for diabetic nephropathy therapy","volume":"13","author":"Chen","year":"2018","journal-title":"Int J Nanomed"},{"key":"B180","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1556-276X-9-247","article-title":"Dendrimers: synthesis, applications, and properties","volume":"9","author":"Abbasi","year":"2014","journal-title":"Nanoscale Res Lett"},{"key":"B181","doi-asserted-by":"publisher","first-page":"683247","DOI":"10.3389\/fbioe.2021.683247","article-title":"Targeted drug delivery systems for kidney diseases","volume":"9","author":"Huang","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"10511","DOI":"10.1073\/pnas.1808168115","article-title":"l-Serine\u2013modified polyamidoamine dendrimer as a highly potent renal targeting drug carrier","volume":"115","author":"Matsuura","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B183","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jconrel.2021.01.002","article-title":"Recent advances of nanomedicine-based strategies in diabetes and complications management: diagnostics, monitoring, and therapeutics","volume":"330","author":"Wang","year":"2021","journal-title":"J Controlled Release"},{"key":"B184","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jfda.2015.01.007","article-title":"Application of polymeric nanoparticles and micelles in insulin oral delivery","volume":"23","author":"Alai","year":"2015","journal-title":"J Food Drug Anal"},{"key":"B185","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.apsb.2020.10.016","article-title":"An injectable micelle-hydrogel hybrid for localized and prolonged drug delivery in the management of renal fibrosis","volume":"11","author":"Qin","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B186","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/gels11020124","article-title":"Nanogels\u2014innovative drug carriers for overcoming biological membranes","volume":"11","author":"Radeva","year":"2025","journal-title":"Gels"},{"key":"B187","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/pharmaceutics14040883","article-title":"Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence","volume":"14","author":"Alshawwa","year":"2022","journal-title":"Pharmaceutics"},{"key":"B188","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.3390\/molecules29204854","article-title":"Enhancing drug solubility, bioavailability, and targeted therapeutic applications through magnetic nanoparticles","volume":"29","author":"Zhuo","year":"2024","journal-title":"Molecules"},{"key":"B189","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1039\/C7FO01652B","article-title":"Zein-derived peptides as nanocarriers to increase the water solubility and stability of lutein","volume":"9","author":"Jiao","year":"2018","journal-title":"Food Funct"},{"key":"B190","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/2405461504666190527101436","article-title":"Nanocarriers based novel drug delivery as effective drug delivery: a review","volume":"4","author":"Shirsath","year":"2019","journal-title":"Curr Nanomat"},{"key":"B191","doi-asserted-by":"publisher","first-page":"e112274","DOI":"10.5812\/amh.112274","article-title":"A brief review on advantages of nano-based drug delivery systems","volume":"19","author":"Hami","year":"2021","journal-title":"Ann Mil Health Sci Res"},{"key":"B192","doi-asserted-by":"publisher","first-page":"8572","DOI":"10.1039\/C5RA23580D","article-title":"Magnetic conducting polymer\/mesoporous SiO 2 yolk\/shell nanomaterials: multifunctional nanocarriers for controlled release of doxorubicin","volume":"6","author":"Zhang","year":"2016","journal-title":"RSC Adv"},{"key":"B193","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1039\/C3NR05961H","article-title":"Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicity","volume":"6","author":"Sethi","year":"2014","journal-title":"Nanoscale"},{"key":"B194","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21315\/jps2020.31.2.1","article-title":"Amino-starch nanoparticles as controlled release nanocarriers for curcumin","volume":"31","author":"Kemin","year":"2020","journal-title":"J Phys Sci"},{"key":"B195","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1515\/ntrev-2015-0055","article-title":"Making drugs safer: improving drug delivery and reducing the side effect of drugs on the human biochemical system","volume":"5","author":"Odiba","year":"2016","journal-title":"Nanotechnol Rev"},{"key":"B196","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/jphp.13098","article-title":"An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites","volume":"71","author":"Attia","year":"2019","journal-title":"J Pharm Pharmacol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat Rev Mater"},{"key":"B198","doi-asserted-by":"publisher","first-page":"664051","DOI":"10.3389\/fbioe.2021.664051","article-title":"Tumor-Acidity responsive polymeric nanoparticles for targeting delivery of angiogenesis inhibitor for enhanced antitumor efficacy with decreased toxicity","volume":"9","author":"Cong","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1039\/D0NJ05169A","article-title":"Stimulus-responsive nanocarriers for targeted drug delivery","volume":"45","author":"Fang","year":"2021","journal-title":"New J Chem"},{"key":"B200","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nmat3776","article-title":"Stimuli-responsive nanocarriers for drug delivery","volume":"12","author":"Mura","year":"2013","journal-title":"Nat Mater"},{"key":"B201","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1039\/C7BM00271H","article-title":"Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease","volume":"5","author":"Wang","year":"2017","journal-title":"Biomater Sci"},{"key":"B202","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/med.21532","article-title":"Targeting strategies for drug delivery to the kidney: from renal glomeruli to tubules","volume":"39","author":"Liu","year":"2019","journal-title":"Med Res Rev"},{"key":"B203","doi-asserted-by":"publisher","first-page":"sfaf192","DOI":"10.1093\/ckj\/sfaf192","article-title":"Pathways to translation for nanomedicine in nephrology","volume":"18","author":"Schoales","year":"2025","journal-title":"Clin Kidney J"},{"key":"B204","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/ndt\/gfac233","article-title":"Targeted nanotherapy for kidney diseases: a comprehensive review","volume":"38","author":"Sabiu","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B205","doi-asserted-by":"publisher","first-page":"585576","DOI":"10.2147\/IJN.S585576","article-title":"Nanoparticles in the treatment of renal fibrosis","volume":"21","author":"Wu","year":"2026","journal-title":"Int J Nanomed"},{"key":"B206","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.7150\/thno.126217","article-title":"Kidney-targeted nanoplatforms: strategies and applications","volume":"16","author":"Deng","year":"2026","journal-title":"Theranostics"},{"key":"B207","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1073\/pnas.1200718109","article-title":"Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane","volume":"109","author":"Zuckerman","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B208","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1021\/acsnano.5b05066","article-title":"Short-and long-term tracking of anionic ultrasmall nanoparticles in kidney","volume":"10","author":"Liang","year":"2016","journal-title":"ACS Nano"},{"key":"B209","doi-asserted-by":"publisher","first-page":"e1953","DOI":"10.1002\/wnan.1953","article-title":"A quantitative review of nanotechnology-based therapeutics for kidney diseases","volume":"16","author":"Cheng","year":"2024","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"B210","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.7150\/thno.37538","article-title":"Kidney-targeted rhein-loaded liponanoparticles for diabetic nephropathy therapy via size control and enhancement of renal cellular uptake","volume":"9","author":"Wang","year":"2019","journal-title":"Theranostics"},{"key":"B211","doi-asserted-by":"publisher","first-page":"1763546","DOI":"10.3389\/fbioe.2026.1763546","article-title":"Kidney-targeted drug delivery: from physiological mechanisms to precision therapeutics","volume":"14","author":"Tan","year":"2026","journal-title":"Front Bioeng Biotechnol"},{"key":"B212","doi-asserted-by":"publisher","first-page":"612146","DOI":"10.2147\/IJN.S612146","article-title":"The current application prospects of nanomedicine in renal ischemia-reperfusion injury","volume":"21","author":"Jiang","year":"2026","journal-title":"Int J Nanomed"},{"key":"B213","doi-asserted-by":"publisher","first-page":"e70210","DOI":"10.1002\/mabi.70210","article-title":"Design of nanocarriers for kidney targeted delivery of nucleic acid therapeutics","volume":"26","author":"Lee","year":"2026","journal-title":"Macromol Biosci"},{"key":"B214","doi-asserted-by":"publisher","first-page":"1508312","DOI":"10.3389\/fphar.2024.1508312","article-title":"Curcumin nanocrystals ameliorate ferroptosis of diabetic nephropathy through glutathione peroxidase 4","volume":"15","author":"Xue","year":"2025","journal-title":"Front Pharmacol"},{"key":"B215","doi-asserted-by":"publisher","first-page":"175289","DOI":"10.1016\/j.ejphar.2022.175289","article-title":"Rutin and selenium nanoparticles protected against STZ-induced diabetic nephropathy in rats through downregulating jak-2\/Stat3 pathway and upregulating nrf-2\/HO-1 pathway","volume":"933","author":"Zaghloul","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3390\/molecules21111517","article-title":"Selenium nanoparticles attenuate oxidative stress and testicular damage in streptozotocin-induced diabetic rats","volume":"21","author":"Dkhil","year":"2016","journal-title":"J Nanosci Nanotechnol"},{"key":"B217","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jconrel.2022.12.012","article-title":"Nanocurcumin combined with insulin alleviates diabetic kidney disease through P38\/P53 signaling axis","volume":"353","author":"Ganugula","year":"2023","journal-title":"J Controlled Release"},{"key":"B218","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.2147\/IJN.S91377","article-title":"Anti-hyperglycemic activity of selenium nanoparticles in streptozotocin-induced diabetic rats","volume":"10","author":"Al-Quraishy","year":"2015","journal-title":"Int J Nanomed"},{"key":"B219","doi-asserted-by":"publisher","first-page":"e23430","DOI":"10.1002\/jbt.23430","article-title":"Promising renoprotective effect of gold nanoparticles and dapagliflozin in diabetic nephropathy via targeting miR-192 and miR-21","volume":"37","author":"Al-Tantawy","year":"2023","journal-title":"J Biochem Mol Toxicol"},{"key":"B220","doi-asserted-by":"publisher","first-page":"37330","DOI":"10.1021\/acsami.2c06957","article-title":"Adropin carried by reactive oxygen species-responsive nanocapsules ameliorates renal lipid toxicity in diabetic mice","volume":"14","author":"Yu","year":"2022","journal-title":"ACS Appl Mater Interfaces"},{"key":"B221","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s13346-019-00675-6","article-title":"Gold nanoparticles attenuate albuminuria by inhibiting podocyte injury in a rat model of diabetic nephropathy","volume":"10","author":"Alomari","year":"2020","journal-title":"Drug Deliv Transl Res"},{"key":"B222","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12951-025-03108-4","article-title":"RGD-HSA-TAC nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney disease","volume":"23","author":"Guo","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B223","doi-asserted-by":"publisher","first-page":"17696","DOI":"10.1007\/s00210-025-04356-9","article-title":"Carvedilol-loaded self-nanoemulsifying drug delivery system target diabetic nephropathy: preclinical evidence of antioxidant and antifibrotic effects","volume":"398","author":"Elimam","year":"2025","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"B224","doi-asserted-by":"publisher","first-page":"1351497","DOI":"10.3389\/fendo.2024.1351497","article-title":"Application and design considerations of ROS-based nanomaterials in diabetic kidney disease","volume":"15","author":"Huang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B225","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1681\/ASN.0000000608","article-title":"Nanotherapeutics in kidney disease: innovations, challenges, and future directions","volume":"36","author":"Roointan","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B226","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12951-023-02257-8","article-title":"Application of nanotechnology in the treatment of glomerulonephritis: current status and future perspectives","volume":"22","author":"Zhan","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"B227","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.18632\/aging.205535","article-title":"Exosomes as nanostructures deliver miR-204 in alleviation of mitochondrial dysfunction in diabetic nephropathy through suppressing methyltransferase-like 7A-mediated CIDEC N6-methyladenosine methylation","volume":"16","author":"Jin","year":"2024","journal-title":"Aging (albany ny)"},{"key":"B228","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/nat.2014.0505","article-title":"siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA","volume":"25","author":"Zuckerman","year":"2015","journal-title":"Nucleic Acid Ther"},{"key":"B229","doi-asserted-by":"publisher","first-page":"13769","DOI":"10.3390\/molecules181113769","article-title":"The Janus face of PAMAM dendrimers used to potentially cure nonenzymatic modifications of biomacromolecules in metabolic disorders\u2014a critical review of the pros and cons","volume":"18","author":"Labieniec-Watala","year":"2013","journal-title":"Molecules"},{"key":"B230","doi-asserted-by":"publisher","first-page":"102208","DOI":"10.1016\/j.nano.2020.102208","article-title":"Reperfusion combined with intraarterial administration of resveratrol-loaded nanoparticles improved cerebral ischemia\u2013reperfusion injury in rats","volume":"28","author":"Lu","year":"2020","journal-title":"Nanomedicine"},{"key":"B231","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/00325481.2024.2377529","article-title":"Clinical trial designs of emerging therapies for diabetic kidney disease (DKD)","volume":"136","author":"Singh","year":"2024","journal-title":"Postgrad Med"},{"key":"B232","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"B233","author":"Tuttle","year":"2023","journal-title":"Randomized trial of semaglutide for diabetic kidney disease in type 1 diabetes"},{"key":"B234","doi-asserted-by":"publisher","first-page":"i59","DOI":"10.1093\/ndt\/gfae258","article-title":"Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease","volume":"40","author":"Neuen","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B235","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1021\/acsnano.9b08133","article-title":"Nanomaterials for nanotheranostics: tuning their properties according to disease needs","volume":"14","author":"Wong","year":"2020","journal-title":"ACS nano"},{"key":"B236","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1021\/acs.chemrestox.9b00438","article-title":"Review on metal-based nanoparticles: role of reactive oxygen species in renal toxicity","volume":"33","author":"Makhdoumi","year":"2020","journal-title":"Chem Res Toxicol"},{"key":"B237","doi-asserted-by":"publisher","first-page":"7873","DOI":"10.1166\/jnn.2016.13032","article-title":"Toxicity of inorganic nanoparticles used in targeted drug delivery and other biomedical application: an updated account on concern of biomedical nanotoxicology","volume":"16","author":"Ahmad","year":"2016","journal-title":"J Nanosci Nanotechnol"},{"key":"B238","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2217\/nnm-2023-0251","article-title":"Nanocarrier-based localized and effective treatment of renal disorders: currently employed targeting strategies","volume":"19","author":"Ullah","year":"2024","journal-title":"Nanomedicine"},{"key":"B239","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1161\/HYPERTENSIONAHA.122.17944","article-title":"Novel drug delivery technologies and targets for renal disease","volume":"79","author":"Chade","year":"2022","journal-title":"Hypertension"},{"key":"B240","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00210-024-03532-7","article-title":"Exploring cutting-edge approaches in diabetes care: from nanotechnology to personalized therapeutics","volume":"398","author":"Asaad","year":"2025","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"B241","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/978-981-16-8984-0_18","article-title":"Nanotechnology for personalized medicine","volume-title":"Nanomedicine","author":"Shrestha","year":"2023"}],"container-title":["Frontiers in Medical Technology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2026.1951734\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:48:03Z","timestamp":1787658483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2026.1951734\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":241,"alternative-id":["10.3389\/fmedt.2026.1951734"],"URL":"https:\/\/doi.org\/10.3389\/fmedt.2026.1951734","relation":{},"ISSN":["2673-3129"],"issn-type":[{"value":"2673-3129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1951734"}}